禁闭岛'In-Depth Narcotics Experience': McKinsey Advised US Pharmas on How to Turbo Sell Opioids_我的网站
一 | Kenny 报道 奥克兰一位律师“拙劣地”让自己成为其客户全部遗产的唯一受益人，导致客户两个女儿身无分文。 Global consulting giant McKinsey & Company advised several painkillers producers for 15 years on how to "turbocharge" prescription drug sales largely to blame for starting the opioid epidemic in the US, The New York Times has revealed citing over 100,000 documents.,The docs emerged as a part of a settlement deal that McKinsey signed with several state attorneys that sued the company.,Apart from working with Endo, Purdue, and Mallinckrodt, the company also provided "in-depth experience in narcotics" for Johnson & Johnson subsidiaries producing controlled substances. Meanwhile, hundreds of thousands of US citizens died from overdose, often linked to these very drugs.,How It All Started,According to the disclosed documents, McKinsey helped both Endo and Purdue, the creators of two of the most widespread opioid-based drugs for severe chronic pain, to launch their products Opana and OxyContin in 2006-2008. The firm even advised one of the companies on how to overcome a Food and Drug Administration (FDA) block which it had encountered in 2008.,The FDA blocked Purdue's attempt to release an upgraded version of its OxyContin, which was more difficult to snort or dilute and inject in bloodstream – two methods of the prescription drug's abuse that already had been devised by some of its recipients. In order to help Purdue get the license, McKinsey interviewed an ex-drug dealer on the medication's abuse, prepared docs and even coached the drug firm's officials for meetings with the FDA as the pharmaceutical company knew its drug had been widely abused, the docs suggest.,Crack Pipes: Biden Administration's Handling of US Opioid Crisis Raising Questions, Journo Says15 February, 13:00 GMT,Purdue's main competitor, Endo, also released a new version of its painkiller and tried to get it marked as resistant to crushing (for snorting) and diluting (for injections), but the FDA did not allow the latter citing lack of such properties. Nonetheless, the drug's release was a success and coincided with a drop in abuse-resistant OxyContin's sales.,This came, however, at a cost of local epidemics of previously unseen blood disorders in several US states in 2012 – patients were found to be anemic and suffered from kidney failure. Many of them admitted to abusing updated Opana – the new formulae indeed discouraged from snorting it, but still allowed injection abuse. However, the same component that prevented crushing took a great toll on those who tried to inject the drug to get a better high, leading to red blood cells' destruction and organ damage.,Going on the 'Offensive',The consulting company's involvement in the opioid crisis did not stop at helping the companies to launch their products – it also helped them to boost the sales.,While the pills like the ones produced by Endo, Purdue and Mallinckrodt were originally advertised as not causing additions, US doctors were not always prone to prescribing them, especially when a patient's pain was neither severe nor chronic. According to the revealed documents, McKinsey's consultants helped Purdue, and several other companies, including two J&J subsidiaries, to overcome this "problem".,Starting in 2009, McKinsey developed a "segmentation" strategy for Purdue: its analysts divided the company's customers into groups based on their potential thoughts of the product and then formed distinct messages for each group. The customers in this case were doctors prescribing painkillers and the product was opioid drugs. The strategy targeted even doctors who resorted to opioids only in most extreme cases, ensuring them of OxyContin's safety and trying to convince them that there was no point in making their patients suffer.,The consulting company proposed to achieve this by "[raising] physician comfort levels through appropriate education and support". Purdue tried to convince these doctors that their colleagues had no issues prescribing OxyContin.,By 2014, the US government started to realize a nascent opioid drug problem was underway and introduced new labeling requirements for such drugs as well as instructions to use them only in cases of severe of chronic pain. Around the same time, OxyContin sales started to decline, prompting Purdue to ask for McKinsey's help once again – this time to overcome the government's policy and precautions.,The consultants identified the problem as the company promoting its drug as a less potent opioid amid rampant drug abuse and advised to shift to the "offense" instead, the documents show. They namely advised focusing the salesmen efforts on doctors, who were likely to prescribe OxyContin to a new client not previously taking opioid drugs.,"Physicians with higher OxyContin NBRx to Rx ratio may be more likely to initiate a patient on OxyContin", an extract from a McKinsey presentation for Purdue from January 2014 said.,Around the same time and amid the 2015 HIV concentrated outbreaks in several states linked to the opioid drugs abuse via injections, McKinsey consulted Endo on promoting its Opana. The company was not concerned about what the CDC named "explosive transmission" of HIV and the Opana's role in it, according to the documents. On the contrary, in summer 2015, it helped Endo rededicate most of its salesmen from other products into a "Sales Force Blitz" – the company almost solely dedicated to selling Opana to around 3,000 physicians in the US.,One of McKinsey's consultants was excited over the creation of the "Force", claiming in correspondence with the head of Endo’s painkiller unit that the "fun [begins] on Monday!" with the latter responding "agreed, the fun is just beginning".,Playing Both Sides,One of the strangest revelations in the documents uncovered by the New York Times is that McKinsey managed to play both sides of the opioid crisis tragedy – helping pharmaceutical companies sell more of "not-so-addiction-resistant" drugs, while also assisting the FDA, other government agencies and state governments, in the fight against the epidemic.,In 2017, the FDA finally decided to pull one of the drugs, the more potent Opana, from the market, but not until it made $844 million in revenue with help from McKinsey and played a role in the deaths of thousands of Americans, considered to be the victims of the opioid epidemic. Paradoxically, the same year, McKinsey Senior Partner Tom Latkovic lamented about doctors prescribing opioid painkillers left and right at a health care conference.,"Why do we continue to prescribe, dispense, pay for opioid prescriptions to people that we know, or at least we could know, have an incredibly high propensity to abuse them?" Latkovic wondered.,The bizarre divergence between what McKinsey was advising to the pharmaceutical companies and Latkovic's rhetoric is explained by the fact that he was not a member of the consulting company's pharmaceutical practice, which worked with pharma.,Instead, he and his team worked with state governments and health systems to pin down the ways of tackling the opioid crisis, The New York Times said citing two local officials, who used to work on the issue. Their work, however, was partly complicated by McKinsey's pharmaceutical wing, which wanted to greenlight their draft publications in case they could damage their clients.,North Carolina Rep. Claims Opioid Crisis 'Affects Every Community' in US Amid Drug Trafficking Surge19 December 2021, 01:36 GMT,Eventually in 2019, McKinsey finally stopped advising its top client, Perdue, but not until their ties became public during one of the litigations related to the opioid epidemic and initiated by US authorities. One such litigation eventually had McKinsey pay $600 million in settlement without admitting guilt, as well as release the documents related to its work with the pharmaceutical companies.。
二 | 法院要求他为这一荒谬错误支付2.2万纽币。 本周律师和产权事务纪律法庭谴责了韩裔律师Joseph Boaz Park（朴姓）的神操作，法庭称他“拙劣地起草”的遗嘱极为“古怪”。 Advertise with us 法庭文件显示，一名79岁的韩裔老婆婆于2020年1月找到朴律师，希望用自己的住房申请反向抵押贷款同时起草一份遗嘱。
三 | 朴律师主要从事产权转让业务，在遗产法和遗嘱方面的经验十分有限。 3月下旬，老婆婆向朴律师提供了一份用韩文写成的遗嘱草稿，详细说明了她希望遗产在两个女儿之间进行分配。 朴律师随后向她提供了英文版遗嘱，由自己作为执行人，并交给老婆婆签字。这份英文版遗嘱没有提供韩文对应副本。 英文遗嘱上写着，该女子希望“将我的全部财产给予、遗赠和交托给……我所说的律师”。 4月老婆婆因末期癌症去世，她的女儿们对遗嘱产生了疑问。他们指责朴律师策划了有利于他的遗嘱。 但法庭听证会上，朴律师对不当行为指控进行自辩。他说自己缺乏起草遗嘱的经验，并不是有心欺骗当事人家属。听证会还发现他的雇主律所对此事监管不力。 尽管客户家属对朴律师提出了多达10项指控，但法庭在责任认定书中表示：“我们没有发现任何可质疑朴先生作为执业者存在品格问题。” 但朴律师仍然因两方面的不当行为被判违纪：起草遗嘱的能力存在问题；对自己管理的遗产的受益人缺乏礼貌。 （图片来源：NZ Herald） 后一个不当行为主要发生在朴律师和客户大女儿之间。大女儿是一名传教士，母亲去世时正在海外。她回到新西兰后和朴律师的关系一开始就不顺利，之后更是提出多项指控。 最让大女儿质疑的是母亲为何会在弥留前申请反向抵押贷款。
四 | 该贷款又称以房养老，由老人以自住房或土地作为抵押，向金融机构申请融资。
五 | 老人健在时只需每月支付利息，无需偿还本金；老人去世后需以出售物业所得来归还贷款本金。
六 | 朴律师非常粗鲁的表示他不知道答案，他对大女儿说等她去天堂遇到母亲时，这些问题可以自己去问。身为基督徒的女儿当即被震惊到了。 整个交流过程双方都使用韩文，在书面联系时朴律师也是用的韩文。——尽管大女儿表示反对，并要求朴律师使用英文。 朴律师反对了大女儿的反对，他在电子邮件中写道：“也许你的外国人丈夫一直从中搞事……” 法庭认为“外国人丈夫”这个措辞的韩文表达没有英文表达这么冒犯，因此推定朴律师不是恶意的。但还是指出，他应该用客户家属要求的语言进行交流。 本周法庭做出处罚决定，决定称尽管朴律师在起草委托人的遗嘱时不称职，但整体表现显示他确有努力兑现委托人的遗愿。 判决书称：“简而言之，朴先生拙劣地起草了一份遗嘱，造成将整个遗产留给他自己的结果。” “当律师在不熟悉的领域从事工作时，总是存在职业错误风险。本决定传达的信息是，即使任务看似简单，律师也必须小心谨慎和寻求协助。
七 | ” 判决书称朴律师是一名诚实勤奋的法律从业者，但行为表现出一定程度的僵化，而且拒不认错。 “他不愿承认错误或缺点。他在起草遗嘱方面的无能导致了古怪的结果，但他的行为表明其本意一直是执行客户的遗愿，因此不存在损失风险。” 法庭建议朴律师尊重客户家属的要求，用英文而不是韩文来进行交流；哪怕他自己觉得使用韩文“更舒坦”。
八 | 最终法庭要求朴律师支付5000纽币罚款和支付1.7万纽币的法律费用，并要求他的雇主律所监督他未来两年的工作。 朴律师在庭后发布声明，称他尊重法庭判决和对他提出的建议。 注：本文为编译/原创，欢迎转发分享；但严禁复制等未经授权的非法使用。违反上述声明者，本网将追究其相关法律责任。使用授权请联系[email protected]。 chineseherald.co.nz All Rights Reserved 版权所有 (责编：twinkle) 相关内容 员工润去了黄金海岸，奥克兰市议会允许其远程工作 住豪宅、开法拉利，奥克兰华人毒枭承认是贩毒集团头目 奥克兰北岸绑架案：一男一女在酒吧被捕，绑架动机是...... 彩虹活动被取消、人行道被破坏，新西兰仇恨犯罪又回来了？ 可怕！北岸发生绑架案！还有人开枪！ 疫情通报：过去一周新西兰新增3399例 总理公布未来三个月的“行动计划”，重点关注三个领域 新西兰“宝藏半岛”命运未决 知名大导演斥巨资购买取景地。 Current article:http://8b4os.mexuanmeixuyaopinzheng.shop/xdwou/20260826/9578257.html Published on:00:50:47 |
